Liang C, Yu D, Yu T, Li J, Xue L
Quant Imaging Med Surg. 2024; 14(12):9667-9684.
PMID: 39698656
PMC: 11652033.
DOI: 10.21037/qims-24-993.
Yoshida T, Yoshida S, Inukai K, Kato K, Yura Y, Hattori T
FASEB J. 2024; 38(22):e70192.
PMID: 39556326
PMC: 11599786.
DOI: 10.1096/fj.202402103R.
Eliseev M, Zhelyabina O, Kirillova I, Korsakova Y, Cheremushkina E
Dokl Biochem Biophys. 2024; 517(1):148-155.
PMID: 38861149
DOI: 10.1134/S1607672924700881.
Saldarriaga-Giraldo C, Ramirez-Ramos C, Gallego C, Castilla-Agudelo G, Aranzazu-Uribe M, Saldarriaga-Betancur S
Arch Peru Cardiol Cir Cardiovasc. 2024; 1(2):85-93.
PMID: 38572331
PMC: 10986356.
DOI: 10.47487/apcyccv.v1i2.53.
Stastna M
FEBS J. 2024; 292(1):28-46.
PMID: 38440918
PMC: 11705224.
DOI: 10.1111/febs.17108.
Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.
Guo H, Zhu M, Yu R, Li X, Zhao Q
Front Cardiovasc Med. 2023; 10:1255940.
PMID: 38054101
PMC: 10694238.
DOI: 10.3389/fcvm.2023.1255940.
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Ahmad Cheema H, Shafiee A, Teymouri Athar M, Rafiei M, Mehmannavaz A, Jafarabady K
Front Cardiovasc Med. 2023; 10:1273781.
PMID: 37900570
PMC: 10602781.
DOI: 10.3389/fcvm.2023.1273781.
Heart Failure With Preserved Ejection Fraction: An Evolving Understanding.
Tah S, Valderrama M, Afzal M, Iqbal J, Farooq A, Lak M
Cureus. 2023; 15(9):e46152.
PMID: 37900404
PMC: 10613100.
DOI: 10.7759/cureus.46152.
Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment.
Medarametla G, Kahlon R, Mahitha L, Shariff S, Vakkalagadda N, Chopra H
EXCLI J. 2023; 22:781-808.
PMID: 37720240
PMC: 10502203.
DOI: 10.17179/excli2023-6284.
Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk.
Li J, Qu X, Gao Z, Chen C, Zhang F, Cheng L
Front Pharmacol. 2023; 14:1084442.
PMID: 36778020
PMC: 9911545.
DOI: 10.3389/fphar.2023.1084442.
Vascular dysfunction in HFpEF: Potential role in the development, maintenance, and progression of the disease.
Saavedra-Alvarez A, Pereyra K, Toledo C, Iturriaga R, Del Rio R
Front Cardiovasc Med. 2023; 9:1070935.
PMID: 36620616
PMC: 9810809.
DOI: 10.3389/fcvm.2022.1070935.
A potential role of autophagy-mediated vascular senescence in the pathophysiology of HFpEF.
Sanhueza-Olivares F, Troncoso M, La Fuente F, Martinez-Bilbao J, Riquelme J, Norambuena-Soto I
Front Endocrinol (Lausanne). 2022; 13:1057349.
PMID: 36465616
PMC: 9713703.
DOI: 10.3389/fendo.2022.1057349.
The overestimation of concentric hypertrophy in patients with HFpEF as determined by 2D-echocardiography.
Mathbout M, Hennawi H, Khedr A, Vaidya G, Stoddard M
Glob Cardiol Sci Pract. 2022; 2022(1-2):e202211.
PMID: 36339671
PMC: 9629297.
DOI: 10.21542/gcsp.2022.11.
Assessment of Myocardial Diastolic Dysfunction as a Result of Myocardial Infarction and Extracellular Matrix Regulation Disorders in the Context of Mesenchymal Stem Cell Therapy.
Piatek-Matuszak P, Paslawski R, Paslawska U, Kiczak L, Plociennik M, Janiszewski A
J Clin Med. 2022; 11(18).
PMID: 36143077
PMC: 9502668.
DOI: 10.3390/jcm11185430.
A Computationally Efficient Approach to Simulate Heart Rate Effects Using a Whole Human Heart Model.
Yao J, Chen S, Guccione J
Bioengineering (Basel). 2022; 9(8).
PMID: 35892747
PMC: 9331290.
DOI: 10.3390/bioengineering9080334.
In-hospital Outcomes and Arrhythmia Burden in Patients with Obstructive Sleep Apnea and Heart Failure with Preserved Ejection Fraction.
Gill J, Wu C
J Innov Card Rhythm Manag. 2022; 13(6):5033-5040.
PMID: 35765586
PMC: 9221201.
DOI: 10.19102/icrm.2022.130602.
Targeting the vasculature in cardiometabolic disease.
Boutagy N, Singh A, Sessa W
J Clin Invest. 2022; 132(6).
PMID: 35289308
PMC: 8920329.
DOI: 10.1172/JCI148556.
Myofilament Phosphorylation in Stem Cell Treated Diastolic Heart Failure.
Soetkamp D, Gallet R, Parker S, Holewinski R, Venkatraman V, Peck K
Circ Res. 2021; 129(12):1125-1140.
PMID: 34641704
PMC: 8666591.
DOI: 10.1161/CIRCRESAHA.119.316311.
Similarities and Differences Between HFmrEF and HFpEF.
Li P, Zhao H, Zhang J, Ning Y, Tu Y, Xu D
Front Cardiovasc Med. 2021; 8:678614.
PMID: 34616777
PMC: 8488158.
DOI: 10.3389/fcvm.2021.678614.
Validation of the 2016 ASE/EACVI Guideline for Diastolic Dysfunction in Patients With Unexplained Dyspnea and a Preserved Left Ventricular Ejection Fraction.
van de Bovenkamp A, Enait V, de Man F, Oosterveer F, Bogaard H, Vonk Noordegraaf A
J Am Heart Assoc. 2021; 10(18):e021165.
PMID: 34476984
PMC: 8649534.
DOI: 10.1161/JAHA.121.021165.